The Latest Cardiac and Vascular News
Budiodarone shown in Phase 2 to reduce atrial fibrillation symptoms and long episodes of atrial fibrillation (LEAF) FDA gives guidance on steps necessary to gain approval and incorporate wearable AF monitoring devices into label for budiodarone Five granted US patents align with FDA’s…
LOS ALTOS, Calif., Feb. 26, 2024 /PRNewswire/ — XYRA LLC, a private biopharmaceutical company committed to developing innovative therapies for cardiac rhythm disorders with high unmet need, is pleased to announce today it has reached agreement with the FDA (“Agency”) at a series of End…
